Boston Pharmaceuticals Ph2a MASH Topline Results
Boston Pharmaceuticals announced positive topline results from its Ph2a study (view CT.gov record) evaluating efimosfermin alfa (formerly BOS-580; SC QM FGF21 analog) in participants with F2/F3 fibrosis due to MASH. Of note, results will be presented at AASLD 2024 (Nov 15-19; San Diego, CA) and the company will host an investor event to discuss the data on November 21, 2024 (view webcast). Below, FENIX provides highlights and insights for the topline results.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.